<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-70908" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Thrombin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lopez</surname>
            <given-names>Michael J.</given-names>
          </name>
          <aff>Augusta Un., Medical College of Georgia</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Yandrapalli</surname>
            <given-names>Srikanth</given-names>
          </name>
          <aff>New York Medical College/Westchester Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Michael Lopez declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Srikanth Yandrapalli declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>22</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-70908.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Thrombin is a topical hemostatic agent used to control and minimize blood loss during surgical procedures, is utilized in conjunction or as an alternative to standard surgical techniques. The Federal Drug Administration has approved three thrombin-based products: recombinant thrombin, human thrombin, and bovine thrombin. This activity provides a highlight and discusses critical elements about this drug and how this information can be useful for the medical team involved in the peri- and post-operative care of the patient.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the indications for thrombin use.</p></list-item><list-item><p>Summarize the risks associated with initiating thrombin.</p></list-item><list-item><p>Review the common complications of thrombin use.</p></list-item><list-item><p>Explain the importance of collaboration and communication amongst the interprofessional team to improve outcomes for patients receiving thrombin.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=70908&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=70908">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-70908.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Thrombin is a serine endopeptidase. The enzyme has been extensively studied and researched throughout the years for biotherapeutic purposes.<xref ref-type="bibr" rid="article-70908.r1">[1]</xref>&#x000a0;Bovine thrombin was the first thrombin product approved by the US Federal Drug Administration (FDA) as an ancillary aid for topical hemostasis during surgical procedures in 1943.<xref ref-type="bibr" rid="article-70908.r2">[2]</xref><xref ref-type="bibr" rid="article-70908.r3">[3]</xref>&#x000a0;Adverse immunologic reactions against bovine thrombin fostered the development of human thrombin, approved by the FDA in 2007, and recombinant thrombin, approved by the FDA in 2008.<xref ref-type="bibr" rid="article-70908.r3">[3]</xref><xref ref-type="bibr" rid="article-70908.r4">[4]</xref>&#x000a0;The US FDA has approved these products for hemostasis and minor bleeding control whenever oozing blood from venules and capillaries are accessible or when standard surgical techniques cannot contain the bleeding.<xref ref-type="bibr" rid="article-70908.r4">[4]</xref><xref ref-type="bibr" rid="article-70908.r3">[3]</xref><xref ref-type="bibr" rid="article-70908.r2">[2]</xref>&#x000a0;Thrombin products have approval for use in combination with absorbable hemostatic agents, and this includes gelatin sponge, microfibrillar collagen, and oxidized regenerated cellulose.<xref ref-type="bibr" rid="article-70908.r2">[2]</xref>&#x000a0;Due to their porous structures, these hemostatic agents provide the required architecture for platelet aggregation and coagulation factors activation. Thrombin products are also utilized for the treatment of pseudoaneurysms (PSA).<xref ref-type="bibr" rid="article-70908.r5">[5]</xref>&#x000a0;This method of treatment uses a percutaneous injection under ultrasound guidance. Thrombin, when injected into the PSA, quickly forms a fibrin polymer. This treatment is currently non-approved by the FDA.</p>
      </sec>
      <sec id="article-70908.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Thrombin is a serine endopeptidase naturally produced in humans, and it has a crucial role in the coagulation cascade and the complex process of hemostasis. The liver produces it as an inactivated zymogen, prothrombin, and when the coagulation cascade is activated, this protein is split by other proteases, eventually forming thrombin.<xref ref-type="bibr" rid="article-70908.r6">[6]</xref>&#x000a0;Factor IIa, or as commonly known, thrombin, catalyzes the conversion of fibrinogen into fibrin. Subsequently, fibrin forms a network of fibrin monomers stabilized by factor XIIIa, this transglutaminase catalyzes the cross-linking of glutamine and lysine residues.<xref ref-type="bibr" rid="article-70908.r7">[7]</xref>&#x000a0;The development of a fibrin meshwork provided the appropriate architecture for hemostasis platelet activation, aggregation, and thrombus formation.</p>
      </sec>
      <sec id="article-70908.s4" sec-type="Administration">
        <title>Administration</title>
        <p>All three thrombin products, bovine thrombin, human thrombin, and recombinant thrombin, have been approved by the FDA for topical use only and have been currently label as such by the manufactures. Thrombin products can be applied topically as a solution, as a glue in combination with fibrinogen, or sprayed into a mist.<xref ref-type="bibr" rid="article-70908.r8">[8]</xref><xref ref-type="bibr" rid="article-70908.r9">[9]</xref>&#x000a0;A commonly used technique is the utilization of absorbable hemostatic agents.<xref ref-type="bibr" rid="article-70908.r9">[9]</xref>&#x000a0;Percutaneous intra-aneurysmal administration under ultrasound guidance is another technique utilized to provoke a thrombus inside a vascular pseudoaneurysm, and the FDA does not currently approve this technique.</p>
      </sec>
      <sec id="article-70908.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Bovine Thrombin Adverse Effects&#x000a0;</bold>
</p>
        <p>Bovine thrombin can be extremely immunogenic, fostering the creation of antibodies against bovine thrombin.<xref ref-type="bibr" rid="article-70908.r10">[10]</xref>&#x000a0;These antibodies can eventually cross-react with human coagulation proteins.<xref ref-type="bibr" rid="article-70908.r8">[8]</xref>&#x000a0;The clinical sequelae preceding the development of antibodies can range from normal laboratory values and clinical presentation to abnormal coagulation studies,&#x000a0;hemorrhagic complications, thromboembolic events, anaphylaxis, and death.<xref ref-type="bibr" rid="article-70908.r2">[2]</xref>&#x000a0;Antibodies against bovine Factor V and Va have been the most common; however, antibodies against cardiolipin, prothrombin, thrombin galactose alpha 1, 3 galactose have also been documented, increasing the risk of coagulopathies and bleeding disorders.<xref ref-type="bibr" rid="article-70908.r1">[1]</xref></p>
        <p>
<bold>Human Thrombin</bold>
</p>
        <p>Human thrombin, analogous to any other human blood product, is not utterly devoid of the potential risk of transmitting bloodborne diseases. Even when donors are screened and tested for such diseases and individual units of plasma are extensively examined and purified, there still a risk of possible infection, including, in theory, Creutzfeldt-Jakob disease.<xref ref-type="bibr" rid="article-70908.r3">[3]</xref>&#x000a0;Nevertheless, there have been no cases reported of transmission of any bloodborne disease by the utilization of human thrombin.<xref ref-type="bibr" rid="article-70908.r3">[3]</xref>&#x000a0;The FDA has in place strict regulations that help to achieve this goal.&#x000a0;Some of these screening techniques and viral purification practices overseen by the FDA include nucleic acid testing, the utilization of solvent, detergents, nanofiltrations, vapor heat treatment, sterile filtration, and freeze-drying.<xref ref-type="bibr" rid="article-70908.r9">[9]</xref></p>
        <p>
<bold>Recombinant Thrombin</bold>
</p>
        <p>Recombinant thrombin is a sequence of amino acids relative identical to human thrombin, this sequence of amino acid residues is obtainable from modified Chinese hamsters ovary cell line.<xref ref-type="bibr" rid="article-70908.r8">[8]</xref>&#x000a0;This method of obtaining recombinant thrombin increases the risk of hypersensitive reactions in patients with a history of an allergic response to hamster proteins. Likewise, similar to bovine thrombin, there is a production of antibodies to the medication, but there have been no reported adverse reactions to coagulation proteins.<xref ref-type="bibr" rid="article-70908.r11">[11]</xref>&#x000a0;There has been documentation that 21.5% of people receiving bovine thrombin developed antibodies to the drug, whereas only 1.5% produce antibodies to recombinant thrombin.<xref ref-type="bibr" rid="article-70908.r9">[9]</xref>&#x000a0;Furthermore, this product is devoid of theoretical viral transmission risk found in human thrombin.<xref ref-type="bibr" rid="article-70908.r9">[9]</xref></p>
      </sec>
      <sec id="article-70908.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Thrombin products must not be injected intravascularly or utilized within an open vessel due to a high risk of disseminated intravascular coagulation heart failure, cardiac arrest, and thromboembolism.<xref ref-type="bibr" rid="article-70908.r12">[12]</xref>&#x000a0;Recombinant thrombin is contraindicated in patients with know allergic reactions to hamsters proteins. Patients with suspected or known antibodies to bovine thrombin or factor V must avoid bovine thrombin re-exposure. Bovine thrombin is also contraindicated in patients with known sensitivities to bovine material.&#x000a0;Additionally, thrombin-based products must not be used for massive hemorrhages.</p>
      </sec>
      <sec id="article-70908.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients require monitoring for any signs of bleeding, abnormal platelet counts, coagulation parameters, and fibrinogen levels. Patients receiving thrombin-containing products must be monitored for signs of hypersensitive reactions, blood pressure, changes in heart rate, and decrease end-tidal carbon dioxide. Additionally, patients require monitoring for any signs of thromboembolism during and after thrombin has been&#x000a0;administered.&#x000a0;</p>
      </sec>
      <sec id="article-70908.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>There have not been any reported cases of thrombin products, causing an overdose. There are no antidotes available.&#x000a0;</p>
      </sec>
      <sec id="article-70908.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>All three thrombin products, bovine thrombin, human thrombin and, recombinant thrombin, have been widely used across surgical specialties to achieve hemostasis and overcome bleeding during surgical procedures. Consequently, it is essential for the medical team involved in the peri- and post-operative care of the patient to be aware of any adverse reactions to any of the thrombin products.</p>
        <p>Proper monitoring and surveillance of partial thromboplastin time, prothrombin time, the international normalized ratio is crucial due to the risk of coagulopathies related to these products. It is of equal importance for the interprofessional healthcare team to avoid re-exposure in patients with a previous adverse reaction to thrombin and the avoidance of human thrombin in patients with a history of harmful reactions to human blood products. With interprofessional coordination and communication between clinicians, mid-level practitioners, surgeons, nurses, and pharmacists, appropriately managed thrombin use will result in improved patient outcomes while minimizing adverse events.</p>
        <p>In conclusion, thrombin is a great drug that has been used over the decades to accomplish hemostasis. However, it is not absent from adverse effects. Newer bovine thrombin formulations and, in recent years, the development of alternate thrombin products, like human thrombin and recombinant thrombin, provides the patient with a safer drug that enhances clinical outcomes and reduces morbidity and mortality.&#x000a0;</p>
      </sec>
      <sec id="article-70908.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=70908&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=70908">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/70908/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=70908">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-70908.s11">
        <title>References</title>
        <ref id="article-70908.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lundblad</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Bradshaw</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Gabriel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ortel</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Lawson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mann</surname>
                <given-names>KG</given-names>
              </name>
            </person-group>
            <article-title>A review of the therapeutic uses of thrombin.</article-title>
            <source>Thromb Haemost</source>
            <year>2004</year>
            <month>May</month>
            <volume>91</volume>
            <issue>5</issue>
            <fpage>851</fpage>
            <page-range>851-60</page-range>
            <pub-id pub-id-type="pmid">15116244</pub-id>
          </element-citation>
        </ref>
        <ref id="article-70908.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lew</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Weaver</surname>
                <given-names>FA</given-names>
              </name>
            </person-group>
            <article-title>Clinical use of topical thrombin as a surgical hemostat.</article-title>
            <source>Biologics</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>593</fpage>
            <page-range>593-9</page-range>
            <pub-id pub-id-type="pmid">19707440</pub-id>
          </element-citation>
        </ref>
        <ref id="article-70908.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheng</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Meyer-Massetti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kayser</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>A review of three stand-alone topical thrombins for surgical hemostasis.</article-title>
            <source>Clin Ther</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>31</volume>
            <issue>1</issue>
            <fpage>32</fpage>
            <page-range>32-41</page-range>
            <pub-id pub-id-type="pmid">19243705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-70908.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhandari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ofosu</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Mackman</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Doria</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Humphries</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Babu</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Ortel</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Hoffman Van Thiel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Walenga</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Wahi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Teoh</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Fareed</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Safety and efficacy of thrombin-JMI: a multidisciplinary expert group consensus.</article-title>
            <source>Clin Appl Thromb Hemost</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>39</fpage>
            <page-range>39-45</page-range>
            <pub-id pub-id-type="pmid">21078609</pub-id>
          </element-citation>
        </ref>
        <ref id="article-70908.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mishra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pimpalwar</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Ultrasound Guided Percutaneous Injection of Thrombin: Effective Technique for Treatment of Iatrogenic Femoral Pseudoaneurysms.</article-title>
            <source>J Clin Diagn Res</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>TC04</fpage>
            <page-range>TC04-TC06</page-range>
            <pub-id pub-id-type="pmid">28571227</pub-id>
          </element-citation>
        </ref>
        <ref id="article-70908.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krishnaswamy</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The transition of prothrombin to thrombin.</article-title>
            <source>J Thromb Haemost</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>11 Suppl 1</volume>
            <issue>0 1</issue>
            <fpage>265</fpage>
            <page-range>265-76</page-range>
            <pub-id pub-id-type="pmid">23809130</pub-id>
          </element-citation>
        </ref>
        <ref id="article-70908.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Identification of respective lysine donor and glutamine acceptor sites involved in factor XIIIa-catalyzed fibrin &#x003b1; chain cross-linking.</article-title>
            <source>J Biol Chem</source>
            <year>2011</year>
            <month>Dec</month>
            <day>30</day>
            <volume>286</volume>
            <issue>52</issue>
            <fpage>44952</fpage>
            <page-range>44952-64</page-range>
            <pub-id pub-id-type="pmid">22030394</pub-id>
          </element-citation>
        </ref>
        <ref id="article-70908.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bishop</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Schultz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Comparison of recombinant human thrombin and plasma-derived human alpha-thrombin.</article-title>
            <source>Semin Thromb Hemost</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>32 Suppl 1</volume>
            <fpage>86</fpage>
            <page-range>86-97</page-range>
            <pub-id pub-id-type="pmid">16673270</pub-id>
          </element-citation>
        </ref>
        <ref id="article-70908.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ham</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Lew</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Weaver</surname>
                <given-names>FA</given-names>
              </name>
            </person-group>
            <article-title>Thrombin use in surgery: an evidence-based review of its clinical use.</article-title>
            <source>J Blood Med</source>
            <year>2010</year>
            <volume>1</volume>
            <fpage>135</fpage>
            <page-range>135-42</page-range>
            <pub-id pub-id-type="pmid">22282693</pub-id>
          </element-citation>
        </ref>
        <ref id="article-70908.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ortel</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Mercer</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Thames</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Lawson</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin.</article-title>
            <source>Ann Surg</source>
            <year>2001</year>
            <month>Jan</month>
            <volume>233</volume>
            <issue>1</issue>
            <fpage>88</fpage>
            <page-range>88-96</page-range>
            <pub-id pub-id-type="pmid">11141230</pub-id>
          </element-citation>
        </ref>
        <ref id="article-70908.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Croxtall</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Recombinant human thrombin: in surgical hemostasis.</article-title>
            <source>BioDrugs</source>
            <year>2009</year>
            <volume>23</volume>
            <issue>5</issue>
            <fpage>333</fpage>
            <page-range>333-8</page-range>
            <pub-id pub-id-type="pmid">19754221</pub-id>
          </element-citation>
        </ref>
        <ref id="article-70908.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferschl</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Rollins</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Thromboemboli, acute right heart failure and disseminated intravascular coagulation after intraoperative application of a topical hemostatic matrix.</article-title>
            <source>Anesth Analg</source>
            <year>2009</year>
            <month>Feb</month>
            <volume>108</volume>
            <issue>2</issue>
            <fpage>434</fpage>
            <page-range>434-6</page-range>
            <pub-id pub-id-type="pmid">19151266</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
